Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 4/20 | 0.46 |
| ▸ | NPY4R | P50391 | 7/20 | 0.46 |
| ▸ | NPY1R | P25929 | 5/20 | 0.46 |
| ▸ | NPY2R | P49146 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276973 | 1.00 | FURIN (0.46) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL4537978 | 1.00 | FURIN (0.46) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL18350238 | 0.96 | NPY4R (0.49) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29536365 | 0.96 | NPY4R (0.49) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29506967 | 0.96 | NPY4R (0.49) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31198207 | 0.94 | NPY4R (0.46) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30466504 | 0.93 | NPY4R (0.47) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31188460 | 0.93 | NPY4R (0.51) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31188450 | 0.93 | NPY4R (0.51) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31188448 | 0.93 | NPY4R (0.51) | FURINNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | FURIN 2166/4885NPY4R 128/4885NPY1R 381/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | FURIN 2166/4885NPY4R 128/4885NPY1R 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.